Background: Preclinical studies in endometrial cancer (EC) show that metformin reduces
cellular proliferation by PI3K-AKT-mTOR inhibition. We tested the hypothesis that short-term …

Purpose: Endometrioid endometrial cancer is strongly associated with obesity and insulin
resistance. Metformin, an insulin sensitizer, reduces endometrial tumor growth in vitro …

Objective Metformin reduces cancer incidence and improves overall survival in diabetic
patients. In preclinical studies, metformin decreases endometrial cancer (EC) cell growth by …

We conducted a preoperative window study of metformin in endometrial cancer (EC)
patients and evaluated its antiproliferative, molecular and metabolic effects. Twenty obese …

Metformin recently gained traction as potential anti-endometrial cancer agent for its new
applications. However, the underlying mechanisms of the anti-cancer effect of metformin in …

Background Metformin use is associated with reduced cancer risk in several observational
studies of patients with type 2 diabetes. Results from preclinical studies in endometrial …

Background Metformin has been associated with reduced cancer risk. The mechanisms
underlying this cancer protective effect remain unknown. Methods “Window of opportunity” …

Abstract Background High expression of Ki67, a proliferation marker, is associated with
reduced endometrial cancer-specific survival. Pre-surgical metformin reduces tumour Ki-67 …

Background Metformin is a well-tolerated biguanide drug used for decades to treat type 2
diabetes mellitus. In recent years, long-term administration of metformin has been found to …

BACKGROUND Metformin, an antidiabetic drug, decreases the incidence of various cancers
in diabetic patients. Metformin‐induced inhibition of cancer cell proliferation has been …